Artificial intelligence continues to expand rapidly and a new computer vision algorithm is now available to Moscow radiologists in city hospitals. It analy...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Survey of 7,000+ people in Asia shows expectation of early retirement, early deterioration in health Concerns about cost of well-being nu...
Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health Univer...
ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
BetaLife has acquired the rights to human iPSC technology and cell lines from A*STAR BetaLife and A*STAR sign research collaboration agreement to jointl...
Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and acc...
HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) The EC and the FDA previously granted...
Orion Health, a global leader in population health software, is strengthening its position in North America with new technology and the appointment of Jame...
ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential, will present t...
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three...
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 Carina B...
© 2024 Biopharma Boardroom. All Rights Reserved.
